Rezolute, Inc. Stock News

Wise investors are placing some biotech stocks on their watchlists this month, as these companies have surged over 160%. With more predicted upside to these companies than we see today, one could book

Rezolute is a clinical-stage biotechnology company focused on metabolic diseases related to glucose control. Their lead asset, RZ358, is a monoclonal antibody being developed as a treatment for hyperi

REDWOOD CITY, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential

Initiated Phase 2 proof-of-concept study of RZ402

REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to

REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential

Rezolute, Inc. (RZLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Rezolute, Inc. (RZLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Announced a $130 million registered direct offering and concurrent private placement priced at-the-market

Upgrades According to TD Securities, the prior rating for John Hancock Financial Opportunities Fund (NYSE:BTO) was changed from Buy to Action List Buy. The stock has a 52-week-high of $52.88 and a 52-

REDWOOD CITY, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential

REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential t

REDWOOD CITY, Calif., May 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential t

Results Presented Today at the Pediatric Endocrine Society’s 2022 Annual Meeting Results Presented Today at the Pediatric Endocrine Society’s 2022 Annual Meeting

Rezolute joins group aimed at helping advance timely access to life-saving therapies for those impacted by rare diseases Rezolute joins group aimed at helping advance timely access to life-saving ther